Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Health plans will need to navigate a difficult financial environment caused by increased healthcare costs and potential ...

Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these ...